R&D | March 28, 2026
AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
As Tracky launches integrated health solution
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
Subscribe To Our Newsletter & Stay Updated
